Dianthus Therapeutics (DNTH) EBITDA Margin (2022 - 2025)
Dianthus Therapeutics' EBITDA Margin came in at -10166.92% for Q3 2025, down 8791.46 percentage points from -1375.46% a year earlier but up 7914.43 percentage points from the prior quarter.
Dianthus Therapeutics (DNTH) EBITDA Margin (2022 - 2025) Analysis & Trends
Over the trailing twelve months to Sep 30, 2025, Dianthus Therapeutics reported EBITDA Margin of -4554.84%, down 3011.53 percentage points year-over-year; for FY2024, it was -1632.21%, up 70.09 percentage points from FY2023.
- Going back by year, EBITDA Margin was -1702.30% in FY2023 (-1485.56 pp) and -216.74% in FY2022.
- The five-year range for quarterly EBITDA Margin is -18081.35% (Q2 2025) to -135.01% (Q4 2022).
- Year-over-year, EBITDA Margin has declined for three consecutive quarters, with an average year-over-year change of -3790.38 percentage points over the last eight quarters.
- The fastest year-over-year change in EBITDA Margin over five years came in Q4 2024 (a gain of 425.66 percentage points), and the weakest in Q2 2025 (a drop of 16890.74 percentage points).
- Business Quant data shows DNTH's EBITDA Margin at -18081.35% (Q2 2025), -2850.39% (Q1 2025) and -2404.98% (Q4 2024) in the three quarters before Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 655.56 Bn | 574.09 Bn | 17.26 Bn | 35.95% |
| 2 | AbbVie | 470.94 Bn | 444.10 Bn | 12.70 Bn | 49.01% |
| 3 | Merck | 367.14 Bn | 321.57 Bn | 12.21 Bn | 6.02% |
| 4 | Novartis Ag | 280.33 Bn | 236.20 Bn | 11.24 Bn | - |
| 5 | Astrazeneca | 257.78 Bn | 231.34 Bn | 12.86 Bn | 33.11% |
| 6 | Amgen | 226.04 Bn | 181.44 Bn | 7.24 Bn | 46.01% |
| 7 | Gilead Sciences | 188.89 Bn | 163.01 Bn | 6.22 Bn | -124.26% |
| 8 | Pfizer | 163.75 Bn | 110.70 Bn | 10.94 Bn | 39.16% |
| 9 | Vertex Pharmaceuticals | 133.68 Bn | 105.69 Bn | 2.84 Bn | 39.10% |
| 10 | Dianthus Therapeutics | 3.76 Bn | 3.71 Bn | - | - |
Historic Data
| Date | Value |
|---|---|
| Sep 30, 2025 | -10,166.92% |
| Jun 30, 2025 | -18,081.35% |
| Mar 31, 2025 | -2,850.39% |
| Dec 31, 2024 | -2,404.98% |
| Sep 30, 2024 | -1,375.46% |
| Jun 30, 2024 | -1,190.61% |
| Mar 31, 2024 | -2,039.13% |
| Dec 31, 2023 | -2,830.63% |
| Sep 30, 2023 | -1,703.46% |
| Jun 30, 2023 | -598.07% |
| Mar 31, 2023 | -744.06% |
| Dec 31, 2022 | -135.01% |
| Sep 30, 2022 | -663.51% |
Dianthus Therapeutics EBITDA Margin API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=ebitda-margin&ticker=DNTH&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "ebitda-margin", "ticker": "DNTH", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=ebitda-margin&ticker=DNTH&period=max&api_key=YOUR_API_KEY");
const data = await res.json();